Literature DB >> 9198160

Pathophysiology of platelet thrombin receptors.

G A Jamieson1.   

Abstract

The evidence is reviewed and a model presented for two distinct receptors being involved in platelet activation induced by alpha-thrombin: a high affinity thrombin receptor constituting approximately 50 copies of a supercomplexed form of GPIb coupled to phospholipase A2 and a moderate affinity receptor constituting approximately 2000 copies of the proteolytically activated, G protein-coupled seven transmembrane domain receptor coupled to phospholipase C. Reasons for the failure of certain studies to detect this role for GPIb are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9198160

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Platelet GP Ib/IX/V complex: physiological role.

Authors:  J Rivera; M L Lozano; J Corral; R González-Conejero; C Martínez; V Vicente
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

2.  Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation.

Authors:  Michael Holinstat; Nancy E Colowick; Willie J Hudson; Dana Blakemore; Qingxia Chen; Heidi E Hamm; John H Cleator
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

3.  PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.

Authors:  Michael Holinstat; Bryan Voss; Matthew L Bilodeau; Joseph N McLaughlin; John Cleator; Heidi E Hamm
Journal:  J Biol Chem       Date:  2006-07-12       Impact factor: 5.157

4.  Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP.

Authors:  John H Cleator; Wen Qin Zhu; Douglas E Vaughan; Heidi E Hamm
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

5.  We can do it together: PAR1/PAR2 heterodimer signaling in VSMCs.

Authors:  Rafal Pawlinski; Michael Holinstat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-12       Impact factor: 8.311

6.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

7.  The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition.

Authors:  M J Whitley; D M Henke; A Ghazi; M Nieman; M Stoller; L M Simon; E Chen; J Vesci; M Holinstat; S E McKenzie; C A Shaw; L C Edelstein; P F Bray
Journal:  J Thromb Haemost       Date:  2018-11-22       Impact factor: 5.824

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.